Abstract:Objective To evaluate the pharmacokinetic profiles and rel-ative bioavailability of fluvastatin in healthy Chinese subjects following o-ral administration of single and multiple doses of prolonged -extended re-lease ( XL) fluvastatin sodium tablets or immediate -release ( IR) cap-sules.Methods This was an open -label, randomized, two-period, two-treatment, crossover study.Twenty -four subjects were orally ad-ministered fluvastatin sodium XL tablet 80 mg qd or IR capsule 40 mg bid for 7 days.The serum concentrations of fluvastatin were determined by LC-MS/MS.The pharmacokinetic parameters and the relative bioavail-ability were calculated by non -compartmental analysis ( NCA ) using WinNonlin program.The statistical comparison of the pharmacokinetic parameters between these two formulations was conducted using SPSS 18.0.Results The pharmacokinetic parameters of fluvastatin after single oral dose of fluvastatin sodium XL tablet 80 mg qd and fluvastatin IR capsule 40 mg bid were as follows:Cmax were (79.00 ±36.83 ), (439.80 ±199.35 ) ng· mL-1;tmax were 3.00,0.50 h;t1/2 were (5.39 ± 2.89), (1.88 ±0.50) h;AUC0-24 h were (347.82 ±134.19 ), (815.25 ±326.30 ) ng· h· mL-1;AUC0-∞ were (342.34 ±146.05), (792.32 ±294.33) ng· h· mL -1, respectively.The pharmacokinetic parameters of fluvastatin after multiple oral doses of fluvastatin sodium XL tablet 80 mg qd and IR capsule 40 mg bid were as follows:Cmax,s were (96.85 ±59.38), (526.54 ±228.08) ng· mL-1;Cav,sswere (18.04 ±8.29), (63.39 ±29.02) ng· mL-1;tmax,ss were 3.00, 0.50 h;t1/2 were (5.13 ±2.69 ), (1.74 ±0.26 ) h; AUCtau,ss were (435.46 ±213.14 ), (1194.11 ± 582.51 ) ng· h· mL-1 , respectively.The relative bioavailabilities of fluvastatin sodium XL tablet 80 mg to IR capsule 40 mg were 43.94%and 38.67%on day 1 ( after single dose administration ) and day 7 ( after reaching steady state ) , respectively.Mild adverse events occurred in this trial.Conclusion Comparing with fluvastatin sodium IR capsues , Cmax of fluvastatin sodium XL tablet was reduced and tmax was prolonged.There was no significant accumulation for XL and IR formulations after multiple doses.

Study on Intestinal Absorption and Liver Distribution of Pravastatin in Rats

Study on Absorption Kinetics of Phenolic Alkaloids from Menispermum Dauricum in Rats' Intestines

Tissue-specific Effects of Atorvastatin on 3-Hydroxy-3-methylglutaryl-coenzyme A Reductase Expression and Activity in Spontaneously Hypertensive Rats

Pharmacokinetics and Bioavailability Study of Danshensu in Rat

Study on Correlation Between in vitro Release and in vivo Absorption of Captopril Delayed-onset, Sustained Release Tablet

Pharmacokinetics and Safety of Pitavastatin Calcium Tablets in Chinese Healthy Volunteers after a Single Oral Dose Administration

Study on Correlation Between {\sl in Vitro} Release and {\sl in Vivo} Absorption of Captopril Delayed--onset, Sustained Release Tablet

Influence of atorvastatin on ion pump activity of smooth muscle cells and intima proliferation after arterial intimal injury

Factors Limiting The Extent Of Absolute Bioavailability Of Pradefovir In Rat

Study on bioequivalence of pravastatin sodium tablets in healthy volunteers

Determination of Pravastatin in Rat Plasma by Solid Phase Extraction and RP-HPLC

Enhancement of fatty acid and cholesterol synthesis accompanied by enhanced biliary but not very-low-density lipoprotein lipid secretion following sustained pravastatin blockade of hydroxymethyl glutaryl coenzyme A reductase in rat liver

Increase or decrease of HDL-cholesterol concentrations during pravastatin treatment depending on the pre-treatment HDL cholesterol levels

The Effect of Inflammatory Bowel Disease and Irritable Bowel Syndrome on Pravastatin Oral Bioavailability: In vivo and in silico evaluation using bottom-up wbPBPK modeling

Tissue distribution of 3- hydroxyandrost 5- en- 17- one succinate (A1998) intralipid after the intravenous injection in rats

Functional Consequences of Pravastatin Isomerization on OATP1B1-Mediated Transport

Studies on Rats Intestinal Absorption of Salvianolic Acid B by HPLC-MS

Study on Absorptive Difference between S-Amlodipine and RS-Amlodipine in Rat Intestine

Study on pharmacokinetics of fluvastatin in healthy subjects after single and multiple doses of porolonged-extended release fluvastatin and immediate-release fluvastatin

Simultaneous Determination of Pravastatin and Its Main Metabolite, 3' α - Isopravastatin in Human Plasma by HPLC - MS

The Effect of Pravastatin on Kidney Function and Urinary Protein of Chronic Kidney Disease